Read news on Zidesamtinib with our app.
Read more in the app
Zidesamtinib demonstrates 94% response rate in TKI-naive patients with advanced ROS1-positive NSCLC
Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease and ROS1 G2032R mutations - EurekAlert!
